Baird raised the firm’s price target on Boston Scientific (BSX) to $120 from $115 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results and said they remain buyers of the shares and with the company firing on all cylinders, it has already offset tariffs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific’s Strong Q1 2025 Performance and Strategic Positioning Justify Buy Rating
- Boston Scientific’s Strong Q1 2025 Performance and Growth Potential Justifies Buy Rating
- Boston Scientific: Strong Financial Performance and Positive Outlook Support Buy Rating
- Boston Scientific’s Strong Growth and Strategic Resilience Earns Buy Rating
- Boston Scientific Reports Strong Q1 2025 Growth